Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Recruiting · NCT06984510 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ningbo No. 1 Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.
Who can take part
Inclusion criteria
- Abdominal ultrasound data available in annual health check-up records
- At least one of the following five metabolic indicators recorded annually:
- Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)
Exclusion criteria
- Age \<20 or \>90 years
- Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)
- Type 2 diabetes mellitus at baseline
- Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)
Where it is running
1 location listed.
- the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000 - Ningbo, Zhejiang, China